Abstract:STUDY OBJECTIVES To determine the incidence of hepatotoxicity in critically ill patients who were treated with voriconazole and to identify potential risk factors for voriconazole-associated hepatotoxicity in these patients. DESIGN Single-center prospective observational study.SETTING Intensive care unit (ICU) in a university-affiliated hospital in Xi'an, China.PATIENTS Sixty-three adults, admitted to the ICU between January 2010 and July 2015, who had an ICU length of stay longer than 3 days, had received voriconazole treatment for at least 3 days, and had at least one trough voriconazole plasma concentration (VPC) measurement.INTERVENTION All patients received CYP2C19 genotyping and were evaluated for the development of hepatotoxicity by assessing liver function tests performed before, during, and after voriconazole therapy.MEASUREMENTS AND MAIN RESULTS Hepatotoxicity was classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade scores and was defined as a CTCAE grade score that had increased by at least 2 grade scores over the baseline score. Hepatotoxicity occurred in 12 (19%) of the 63 patients. Characteristics of the patients who developed hepatotoxicity were compared with those of the patients who did not develop hepatotoxicity by univariate and multivariate Cox regression analyses. In the univariate analysis, Acute Physiology and Chronic Health Evaluation II score, invasive fungal infection classification, CYP2C19 genotype, and trough VPC were identified as the variables, and they were subsequently combined in the multivariate regression analysis. Multivariate Cox regression analysis revealed that hepatotoxicity was independently associated with trough VPC (hazard ratio 1.76, p< 0.001). The relationships between trough VPCs and probability of hepatotoxicity were explored by using logistic regression analysis, and a target VPC upper limit of 4 mg/L was identified. The Kaplan-Meier method for the cumulative incidence of hepatotoxicity showed a significant difference between patients with trough VPCs of 4 mg/L or higher and those with VPCs lower than 4 mg/L (p< 0.001).CONCLUSION Trough VPC was an independent risk factor associated with a greater risk of developing hepatotoxicity in critically ill patients, with a potentially toxic target trough concentration threshold of 4 mg/L identified for this complex population.

Voriconazole-induced severe skin allergy and neurological adverse event in a liver failure patient: A case report.

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Hyperlipidemia Caused by Voriconazole: A Case Report

Successful Voriconazole Treatment of Talaromyces Marneffei Infection in an HIV-negative Patient with Osteolytic Lesions.

Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole

Hepatic dysfunction events associated with voriconazole: a real-world study from FDA adverse event reporting system (FAERS) database

Voriconazole in the treatment of invasive fungal infection in hematologic patients: report of 23 cases

A case of drug-induced myopathy in alcoholic cirrhosis caused by voriconazole

Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit

Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold - A Retrospective Cohort Study

A case of acute pancreatitis induced by voriconazole during treatment of cryptococcal meningitis

Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure.

Voriconazole Combined Glucocorticoid Induced Delirium:Case Report

Enhancing voriconazole therapy in liver dysfunction: exploring administration schemes and predictive factors for trough concentration and efficacy

Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin's lymphoma being treated for invasive pulmonary aspergillosis

Association between trough plasma voriconazole concentration and adverse drug reactions in elderly patients

Posaconazole-associated severe hyperbilirubinemia in acute myeloid leukemia following chemotherapy: A case report.

Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study

Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

Graded isavuconazole introduction in a patient with voriconazole allergy

Case Report: Dose-Dependent Interaction Between Dexamethasone and Voriconazole in Severely Ill Patients with Non-Hodgkin’s Lymphoma Being Treated for Invasive Pulmonary Aspergillosis